New vaccine combo aims to halt early myeloma

NCT ID NCT02886065

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a cancer vaccine (PVX-410) combined with two drugs (citarinostat and lenalidomide) in 19 people with smoldering multiple myeloma, a pre-cancer condition. The goal is to see if the combination is safe and can trigger an immune response against myeloma cells. Researchers will also monitor changes in blood markers to look for signs of disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PVX-410 (cancer vaccine), citarinostat, lenalidomide, and Hiltonol
What this could lead to: If successful, this combination could help control smoldering multiple myeloma and delay or prevent progression to active disease.
What could go wrong: This is a very early phase 1 trial with only 19 participants, focused on safety. The vaccine and drugs may not produce strong immune responses or clinical benefit, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell neoplasm Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMOLDERING MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University Hospital of Cleveland- Seidman Cancer Center

Cleveland, Ohio, 44106, United States
Weill Cornell Medical College

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.